Can-Fite BioPharma American Depositary Shares
CANF
5 hedge funds and large institutions have $2.26M invested in Can-Fite BioPharma American Depositary Shares in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 5 closing their positions.
19% more capital invested
Capital invested by funds: $1.9M → $2.26M (+$356K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
44% less funds holding
Funds holding: 9 → 5 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Taylor Asset Management
Toronto,
Ontario, Canada
|
+$390K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
+$6.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$70K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$41K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$20.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$13.9K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TAM
1
Taylor Asset Management
Toronto,
Ontario, Canada
| $2.11M | +$390K | +56 | +27% |
|
|
MC
2
Menta Capital
San Francisco,
California
| $115K | – | – | – |
|
3
Morgan Stanley
New York
| $14K | – | – | – |
|
|
AG
4
Advisor Group
Phoenix,
Arizona
| $10K | +$6.96K | +1 | New |
|
5
Group One Trading
Chicago,
Illinois
| $5K | – | – | – |
|
|
IA
6
IFP Advisors
Tampa,
Florida
| $3K | -$20.9K | -3 | Closed |
|
|
7
UBS Group
Zurich,
Switzerland
| $1K | -$13.9K | -2 | Closed |
|
|
VKH
8
Virtu KCG Holdings
New York
| – | -$70K | -9 | Closed |
|
|
ARTA
9
A.R.T. Advisors
New York
| – | -$41K | -5 | Closed |
|
|
PCM
10
Prelude Capital Management
New York
| – | -$7K | -1 | Closed |
|
CANF Hedge Fund Activity: Q3 2016 in Review
5 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2016, worth a combined $2.26M — up 19% from $1.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CANF and 1 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Taylor Asset Management, adding an estimated $390K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $70K sold.
- 5 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2016, down from 9 in Q2 2016.
- Funds reported $2.26M of Can-Fite BioPharma American Depositary Shares stock for Q3 2016, up 19% quarter-over-quarter.
- 1 fund opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2016 and 5 closed out, a net change of -4 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2016 was Taylor Asset Management, an estimated $390K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2016 was Virtu KCG Holdings, an estimated $70K sold.
Based on aggregated 13F filings for Q3 2016.